 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12...1112131415161718192021...2930» |
- Ovastat (treosulfan) / Medac
[VIRTUAL] Clinical comparison of Treosulfan focused on PK data (Hall A) - Jan 30, 2021 - Abstract #APBMT2020APBMT_289;
Emcure
- Ovastat (treosulfan) / Medac
[VIRTUAL] Choice of Treosulfan in conditioning for HSCT (Hall A) - Jan 30, 2021 - Abstract #APBMT2020APBMT_287;
Emcure Emcure
- Ovastat (treosulfan) / Medac
[VIRTUAL] DESCRIPTIVE ANALYSIS OF MUCOSITIS AMONG MAC VS RIC CONDITIONING REGIMENS () - Jan 30, 2021 - Abstract #APBMT2020APBMT_135;
Pain secondary to mucositis can be managed with adequate analgesia. Proper nutritional supplement during mucositis must be considered.
- Ovastat (treosulfan) / Medac
[VIRTUAL] FLUDARABINE-TREOSULFAN-THIOTEPA (FTT) VS. BUSULFAN-CYCLOPHOSPHAMIDE-ATG IN THALASSEMIA MAJOR BMT () - Jan 30, 2021 - Abstract #APBMT2020APBMT_131;
Proper nutritional supplement during mucositis must be considered. The results suggests superior clinical outcomes with the FTT regimen in terms of overall and thalassemia-free survival.
- Ovastat (treosulfan) / Medac
[VIRTUAL] THALASSEMIA TREOSULFAN-THIOTEPA-FLUDARABINE CONDITIONING FOR ALLOGENEIC BONE MARROW TRANSPLANT IN THALASSEMIA () - Jan 30, 2021 - Abstract #APBMT2020APBMT_127;
Safety and efficacy of treosulfan-thiotepa- fludarabine (Treo-TT-Flu) based conditioning regimen was compared with patients with busulfan-cyclophosphamide- ATG (Bu-Cy- ATG). Treo- TT- Flu based conditioning achieved better graft function, overall survival and Thalassemia free survival in Thalassemia Major.
- Ovastat (treosulfan) / Medac
[VIRTUAL] TREOSULFAN BASED CONDITIONING FOR ALLOGENIC HEMATOPOETIC STEM CELL TRANSPLANT IN HURLER SYNDROME () - Jan 30, 2021 - Abstract #APBMT2020APBMT_124;
Reports of its use in mucopolysaccharidosis patients is rare. We report that Treosulfan based allogeneic HSCT was safe and effective in our child with severe MPS type 1-Hurler syndrome.
- sirolimus / Generic mfg., cyclosporine / Generic mfg.
[VIRTUAL] HEMATOPOIETIC STEM CELL TRANSPLANT FOR ADULT SICKLE CELL DISEASE: EXPERIENCE FROM INDIA () - Jan 30, 2021 - Abstract #APBMT2020APBMT_91;
Considering the background organ toxicity, RTC is preferred. The risk of graft failure can be ameliorated using pre-transplant immune suppression.
- Ovastat (treosulfan) / Medac
[VIRTUAL] NT5E GENE POLYMORPHISM IMPACTS IMPROVED HSCT OUTCOME IN PATIENTS WITH Β-THALASSEMIA (Hall B) - Jan 30, 2021 - Abstract #APBMT2020APBMT_26;
More significantly, there is a strong correlation between the polymorphisms in the NT5E gene and veracious outcome parameters - both immunological as well as toxicity related. Further studies are ongoing to elucidate the mechanism of the protective effect of this NT5E variant in HSCT outcome in TM.
- Ovastat (treosulfan) / Medac
[VIRTUAL] SKIN TOXICITY IN TREOSULFAN-THIOTEPA-FLUDARABINE- CONDITIONING REGIMEN IN CHILDREN UNDERGOING HSCT (Hall C) - Jan 30, 2021 - Abstract #APBMT2020APBMT_17;
Skin and mucous membrane toxicity occur early in the first 7 days. Targeted nursing protocols with early preventive measures helps in reducing morbidity and mortality.
- azacitidine / Generic mfg.
[VIRTUAL] ALLOGENEIC HSCT OUTCOMES FOR JUVENILE MYELOMONOCYTIC LEUKEMIA ‒ A 10 YEAR SINGLE CENTER EXPERIENCE (Hall A) - Jan 30, 2021 - Abstract #APBMT2020APBMT_15;
Graft rejection remains the most significant barrier to cure. Risk stratification based on molecular diagnosis helps avoid HSCT in children with CBL gene mutation
- Ovastat (treosulfan) / Medac
[VIRTUAL] ADVANCING TOWARDS AN OPTIMAL CURE ‒ HSCT EXPERIENCE IN INHERITED METABOLIC DISORDERS (Hall B) - Jan 30, 2021 - Abstract #APBMT2020APBMT_13;
The overall survival after HSCT for children with IEM was 69% in our cohort. With increasing awareness and early diagnosis, optimal outcomes are feasible with HSCT in low and middle-income countries with no access to lifelong enzyme replacement therapy or gene therapy
- Ovastat (treosulfan) / Medac
[VIRTUAL] FLUDARABINE MELPHALAN VS FLUDARABINE TREOSULFAN AS REDUCED INTENSITY CONDITIONING REGIMENS IN HSCT (Hall B) - Jan 30, 2021 - Abstract #APBMT2020APBMT_9;
Severe mucositis and diarrhoea was significantly less with FT than FM in both MSD/MUD and Haplo groups. FT provided comparable outcomes to FM in the MSD / MUD group in spite of having significantly higher proportion of patients with high / very high DRI and HCT CI.
- | Ovastat (treosulfan) / Medac, Medexus
New P2 trial: FIBRAPLO: Haplo-identical Transplantation in Patients With Myelofibrosis - A Phase 2 Prospective Multicentric Prospective Study (clinicaltrials.gov) - Jan 28, 2021
P2, N=28, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- | Ovastat (treosulfan) / Medac
Retrospective data, Journal: Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT. (Pubmed Central) - Jan 28, 2021
FT provided comparable outcomes to FM in the MSD / MUD group in spite of having significantly higher proportion of patients with high / very high DRI and HCT CI. No abstract available
- || Ovastat (treosulfan) / Medac
Clinical, Journal: Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation. (Pubmed Central) - Jan 27, 2021
TBC combined with thiotepa is highly toxic to the skin with various cutaneous manifestations. The toxicity resolves with no long-term sequela.
- | Immunalon / Provecs Medical, Medac
Journal: Effects of Dietary Isomaltooligosaccharide Levels on the Gut Microbiota, Immune Function of Sows, and the Diarrhea Rate of Their Offspring. (Pubmed Central) - Jan 26, 2021
To investigate the effects of dietary isomaltooligosaccharide (IMO) levels on the gut microbiota, immune function of sows, and the diarrhea rate of their offspring, 120 multiparous gestating pig improvement company (PIC) sows with similar body conditions were selected and fed 1 of 6 diets: a basal diet with no supplement (control, CON), or a diet supplemented with 2.5 g/kg, 5.0 g/kg, 10.0 g/kg, 20.0 g/kg, or 40.0 g/kg IMO (IMO1, IMO2, IMO3, IMO4, or IMO5 group, respectively)...Additionally, the colostrum IgA, IgG, and IgM of sows were positively correlated with the genus g_Parabacteroides, g_Sarcina, and g_Coprococcus but negatively correlated with the genus g_YRC22. These findings indicated that IMO could promote the immune activation and had a significant influence in sows' gut microbiota during perinatal period, which may reduce the diarrhea rate of their offspring.
- | Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
New P1 trial: The Effects of Natesto For Treatment Of Hypogonadism (clinicaltrials.gov) - Jan 21, 2021
P1, N=40, Not yet recruiting, Sponsor: Baylor College of Medicine
- || Ovastat (treosulfan) / Medac
Retrospective data, Review: Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 12, 2021
There was no publication bias among these studies. The current meta-analysis determined that treosulfan-based conditioning regimens could improve the OS in patients with MDS and AML, with lower acute graft-versus-host disease incidence, compared with busulfan-based regimens.
- Ovastat (treosulfan) / Medac
[VIRTUAL] T-Receptor Excisional Circle (TREC) Levels Are Associated with OS, NRM and Relapse in Cord Blood Transplant (CBT) Patients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2077;
Given the crucial role of the thymus in generating and maintaining T cell repertoire integrity, poor thymic function was also correlated with increased risk of relapse. Future interventions should target enhancing thymic function.
- Ovastat (treosulfan) / Medac
[VIRTUAL] T-Receptor Excisional Circle (TREC) Levels Are Associated with OS, NRM and Relapse in Cord Blood Transplant (CBT) Patients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2076;
Given the crucial role of the thymus in generating and maintaining T cell repertoire integrity, poor thymic function was also correlated with increased risk of relapse. Future interventions should target enhancing thymic function.
- Ovastat (treosulfan) / Medac
[VIRTUAL] T-Receptor Excisional Circle (TREC) Levels Are Associated with OS, NRM and Relapse in Cord Blood Transplant (CBT) Patients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2075;
Given the crucial role of the thymus in generating and maintaining T cell repertoire integrity, poor thymic function was also correlated with increased risk of relapse. Future interventions should target enhancing thymic function.
- Ovastat (treosulfan) / Medac
[VIRTUAL] T-Receptor Excisional Circle (TREC) Levels Are Associated with OS, NRM and Relapse in Cord Blood Transplant (CBT) Patients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2074;
Given the crucial role of the thymus in generating and maintaining T cell repertoire integrity, poor thymic function was also correlated with increased risk of relapse. Future interventions should target enhancing thymic function.
- Ovastat (treosulfan) / Medac
[VIRTUAL] T-Receptor Excisional Circle (TREC) Levels Are Associated with OS, NRM and Relapse in Cord Blood Transplant (CBT) Patients () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_2073;
Given the crucial role of the thymus in generating and maintaining T cell repertoire integrity, poor thymic function was also correlated with increased risk of relapse. Future interventions should target enhancing thymic function.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Identification of Treosulfan-Induced Myalgia in Pediatric Hematopoietic Stem Cell Transplantation Using an Electronic Health Record Text Mining Tool. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1022;
Results 114 patients received treosulfan and 92 patients busulfan...44% of patients needed strong acting opiates and adjuvant medicines (e.g. ketamine, clonidine, pregabalin)...Using the CDC, EHRs could be easily screened to detect this previously unknown side effect, proving the effectiveness of the tool. Recognition of treosulfan-induced myalgia is important for timely pain management strategies and improving quality of hospital stay.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Identification of Treosulfan-Induced Myalgia in Pediatric Hematopoietic Stem Cell Transplantation Using an Electronic Health Record Text Mining Tool. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1021;
Results 114 patients received treosulfan and 92 patients busulfan...44% of patients needed strong acting opiates and adjuvant medicines (e.g. ketamine, clonidine, pregabalin)...Using the CDC, EHRs could be easily screened to detect this previously unknown side effect, proving the effectiveness of the tool. Recognition of treosulfan-induced myalgia is important for timely pain management strategies and improving quality of hospital stay.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Identification of Treosulfan-Induced Myalgia in Pediatric Hematopoietic Stem Cell Transplantation Using an Electronic Health Record Text Mining Tool. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1020;
Results 114 patients received treosulfan and 92 patients busulfan...44% of patients needed strong acting opiates and adjuvant medicines (e.g. ketamine, clonidine, pregabalin)...Using the CDC, EHRs could be easily screened to detect this previously unknown side effect, proving the effectiveness of the tool. Recognition of treosulfan-induced myalgia is important for timely pain management strategies and improving quality of hospital stay.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Identification of Treosulfan-Induced Myalgia in Pediatric Hematopoietic Stem Cell Transplantation Using an Electronic Health Record Text Mining Tool. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1019;
Results 114 patients received treosulfan and 92 patients busulfan...44% of patients needed strong acting opiates and adjuvant medicines (e.g. ketamine, clonidine, pregabalin)...Using the CDC, EHRs could be easily screened to detect this previously unknown side effect, proving the effectiveness of the tool. Recognition of treosulfan-induced myalgia is important for timely pain management strategies and improving quality of hospital stay.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Identification of Treosulfan-Induced Myalgia in Pediatric Hematopoietic Stem Cell Transplantation Using an Electronic Health Record Text Mining Tool. () - Jan 9, 2021 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_1018;
Results 114 patients received treosulfan and 92 patients busulfan...44% of patients needed strong acting opiates and adjuvant medicines (e.g. ketamine, clonidine, pregabalin)...Using the CDC, EHRs could be easily screened to detect this previously unknown side effect, proving the effectiveness of the tool. Recognition of treosulfan-induced myalgia is important for timely pain management strategies and improving quality of hospital stay.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Treosulfan-containing regimens for patients with malignant and non-malignant disorders (Auditorium 5) - Jan 7, 2021 - Abstract #EBMT2021EBMT_675;
- Campath (alemtuzumab) / Sanofi, Gamifant (emapalumab) / SOBI
[VIRTUAL] Post‐transplant outcomes of children with primary haemophagocytic lymphohistiocytosis given emapalumab to control disease () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_412;
P=N/A, P2/
Median time to transplant was 100 days (95% CI: 73, 155 days). About 86·4% (19/22) of HSCT recipients engrafted, and 90·9% (20/22) survived following HSCT.
- Orencia (abatacept) / BMS
[VIRTUAL] Abatacept acute graft‐versus‐host disease prophylaxis is feasible and safe when combined with post‐transplant cyclophosphamide in the mobilised peripheral blood haploidentical donor setting () - Jan 5, 2021 - Abstract #BSHI2020BSH-I_93;
P2
Post mobilised peripheral blood stem cell infusion, IV PTCy 50 mg/kg was administered on d+3 and +4, followed by IV tacrolimus 0·03 mg/kg/day infusion from d+5, and IV mycophenolate mofetil 15 mg/kg tds...Three doses of abatacept appears to be feasible and safe in the myeloablative mobilised peripheral blood haploidentical donor setting when combined with PTCy after MAC. A prospective clinical trial is planned.
- | oNKord (inaleucel) / Glycostem, Medac, Korea Kolmar
Enrollment open, Combination therapy, IO biomarker: NK4AML: Natural Killer-cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 29, 2020
P1/2, N=24, Recruiting, Sponsor: Radboud University
A prospective clinical trial is planned. Not yet recruiting --> Recruiting
- [VIRTUAL] T-Replete HLA-Matched Grafts Versus T-Depleted HLA-Mismatched Grafts in Inborn Errors of Immunity: Where Are We Now? () - Dec 20, 2020 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_213;
- [VIRTUAL] Reduced Intensity/Reduced Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute Gvhd () - Dec 20, 2020 - Abstract #TCTASTCTCIBMTR2021TCT_ASTCT_CIBMTR_212;
- || Ovastat (treosulfan) / Medac
Clinical, Review, Journal: Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review. (Pubmed Central) - Dec 17, 2020
No evident adverse lung effects were registered in patients that received simultaneous therapy with HD-Cth and TBI. However, pulmonary function testing and lung toxicity reports were lacking for most of these patients.
- || Ovastat (treosulfan) / Medac
Clinical, Journal: Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. (Pubmed Central) - Dec 16, 2020
However, pulmonary function testing and lung toxicity reports were lacking for most of these patients. The use of an HLA-matched donor is the most important factor to avoid substantial recipient chimerism following treosulfan -or melphalan-based conditioning in primary HLH.
- || Ovastat (treosulfan) / Medac
Clinical, Journal: Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. (Pubmed Central) - Dec 16, 2020
Sequential strategy combining FLAG-IDA and treosulfan may offer a salvage option for few selected patients with active AML; however, high NRM presents a major obstacle to treatment success. Future efforts should focus on reducing NRM by moderating regimen intensity and by better selection of patients.
- | Ovastat (treosulfan) / Medac, Medexus
Enrollment open: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov) - Dec 10, 2020
P2, N=60, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Future efforts should focus on reducing NRM by moderating regimen intensity and by better selection of patients. Not yet recruiting --> Recruiting
- | oNKord (inaleucel) / Glycostem, Medac, Korea Kolmar
Enrollment open: WiNK: A Trial to Evaluate the Safety and Efficacy of oNKord (clinicaltrials.gov) - Nov 22, 2020
P1/2, N=33, Recruiting, Sponsor: Glycostem Therapeutics BV
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| trastuzumab duocarmazine (SYD985) / Byondis
Clinical: Hello, my wife just got randomized to a SYD985 arm in a clinical trial for her2 low breast cancer--would you be open to talking to me a little bit about your experience ? i would appreciate any guidance! many thanks for your time (Twitter) - Nov 21, 2020
- | Enrollment open, Post-transplantation: Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias (clinicaltrials.gov) - Nov 20, 2020
P3, N=25, Recruiting, Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Ovastat (treosulfan) / Medac
Clinical, Journal: Treosulfan-based conditioning in HSCT patients. (Pubmed Central) - Nov 18, 2020
Not yet recruiting --> Recruiting No abstract available
- | oNKord (inaleucel) / Glycostem, Medac, Korea Kolmar
New P1/2 trial: WiNK: A Trial to Evaluate the Safety and Efficacy of oNKord (clinicaltrials.gov) - Nov 17, 2020
P1/2, N=33, Not yet recruiting, Sponsor: Glycostem Therapeutics BV
- |||||||||| Obnitix (MSC-FFM) / Medac
New P3 trial, Stroma: IDUNN: Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (clinicaltrials.gov) - Nov 15, 2020
P3, N=210, Not yet recruiting, Sponsor: medac GmbH
- || Ovastat (treosulfan) / Medac
Clinical, Journal: Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens. (Pubmed Central) - Nov 14, 2020
We conclude that a treosulfan-based conditioning regimen gives excellent DFS in pediatric HSCT performed for a nonmalignant disorder but with substantial mucosal toxicity. In a malignant disorder a treosulfan-based regimen looks promising but larger, preferably randomized, studies are needed to prove efficacy.
- ||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Depois da palestra do Dr Ramasamy no #CPU20 quem aí vai mudar a rotina em relação ao clomid e hipogonadismo no homem infértil? Aguardando também mais resultados da Natesto e das células tronco. @so_uro @ranjithramamd @GlinaSidney @DanielSuslik @conradoandrolo1 @matt_coward (Twitter) - Nov 13, 2020
- || Clinical, Review, Journal, IO Biomarker: Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options. (Pubmed Central) - Nov 6, 2020
Recently, the US Food and Drug Administration (FDA) approved three new drugs for the treatment of HER2-positive MBC: the antibody-drug conjugate trastuzumab deruxtecan and the two tyrosine kinase inhibitors neratinib and tucatinib...Furthermore, novel antibody-drug conjugates and small molecules against HER2 are discussed. These developments coupled with new combination strategies (eg, with CDK4/6 inhibitors or immunotherapy) will change the treatment landscape for patients with HER2-positive MBC very soon and will hopefully further improve clinical outcomes.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Factors Affecting Post-Transplant Relapse of Acute Lymphoblastic Leukemia (ALL) in Children According on the Intensity of Conditioning () - Nov 5, 2020 - Abstract #ASH2020ASH_5456;
Relapse incidence after allo-HSCT with MAC and with RIC is comparable. The most significant factor affecting the risk of relapse is the status of the disease at the moment of allo-HSCT.
- tacrolimus / Generic mfg.
[VIRTUAL] Mesenchymal Stromal Cell (MSC) Compassionate Use in France in Treatment of Steroid-Refractory Graft-Versus-Host-Disease (GVHD) after Approval By the Expert Committee of Société Française De Greffe De Moelle Et Thérapie Cellulaire (SFGM-TC) () - Nov 5, 2020 - Abstract #ASH2020ASH_5412;
All pts received a ciclosporin-based (CSA) GVHD prophylaxis (CSA alone, n=1; CSA + Mycophenolate Mofetil (MMF) or Methotrexate, n=7)...Five pts were still taking corticosteroids, and six were taking additional immunosuppressive molecules (Tacrolimus, Ruxolitinib, Etanercetp, Inolimomab, MMF) at time of MSC infusion...Besides, we included patient suffering from R-cGVHD. Regarding those results, MSC efficacy and safety should be confirmed in a proper clinical trial.
- Obnitix (MSC-FFM) / Medac
[VIRTUAL] Mesenchymal Stromal Cells (MSCs) Experience in France to Prevent Graft Failure after Hematopoietic Stem Cell Transplantation: A Retrospective Study from the MSCs/CTL Group of the Francophone Society SFGM-TC (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4096;
Infusion of MSCs at the time of HSCT to prevent graft failure was safe and effective for 6/7 patients. Larger prospective trials are necessary to confirm MSCs impact on engraftment and graft function.